Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ultibro

- PMLiVE

UK’s Competition and Markets Authority to review AZ/Alexion merger

Proposed acquisition has already received competitions clearance in the US and Canada

- PMLiVE

UK government ‘concerned’ over Elliott Management’s plans for GSK

'Activist' hedge fund Elliott Management has built up a sizeable stake in the British drugmaker

- PMLiVE

AZ, Pfizer/BioNTech COVID-19 vaccines ‘highly effective’ against Indian variant

UK study finds vaccines are likely to be effective in preventing hospitalisation/death

- PMLiVE

BeiGene, Novartis’ tislelizumab report promising topline results in nasopharyngeal cancer

In 2018, 46.9% of global cases of nasopharyngeal cancer occurred in China

- PMLiVE

AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients

SGLT2 inhibitor failed to significantly reduce the number of patients who experienced organ failure or died compared to placebo

- PMLiVE

Sandoz reveals antibiotic manufacturing expansion plans in Europe

Builds on company's previous commitments to drive the long-term future of integrated antibiotics manufacturing in Europe

- PMLiVE

GSK and Medicago’s COVID-19 vaccine shows promising antibody responses in phase 2

Neutralising antibody responses in vaccinated participants were about ten times higher than those seen in a panel of sera from recovering COVID-19 patients

- PMLiVE

US Supreme Court rebuffs Sandoz’s Enbrel biosimilar patent case

Amgen will retain market exclusivity on blockbuster arthritis drug until 2029

- PMLiVE

Sanofi, GSK’s COVID-19 vaccine generates strong immune responses across all age groups

Sanofi/GSK delayed their COVID-19 vaccine programme in December 2020 after the vaccine candidate induced low immune responses in older adults

- PMLiVE

Positive results for GSK/CureVac’s COVID-19 vaccine

Vaccine candidate generated strong immune responses in preclinical testing

- PMLiVE

EU asks AZ to deliver 120 million COVID-19 vaccines by the end of June

The EU has launched a new lawsuit against the drugmaker which could result in financial sanctions

- PMLiVE

AZ, Amgen file first-in-class asthma drug with the FDA

Submission is based on positive results from the companies’ PATHFINDER clinical programme

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links